On July 10, 2025 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), reported that an additional confirmed partial response (PR) has been recorded in the Company’s ongoing ACCENT clinical trial in pancreatic cancer (Press release, Amplia Therapeutics, JUL 10, 2025, View Source;v=4a466cc3f899e00730cfbfcd5ab8940c41f474b6 [SID1234654332]). The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The additional partial response brings the objective response rate to 31%, namely 17 out of 55 patients enrolled in the trial. This compares very favourably to chemotherapy alone where a 23% response rate was reported in the benchmark MPACT study1.

A confirmed partial response is a formal designation of response where tumour shrinkage >30% is recorded and sustained for two (2) or more months and where no new cancerous lesions have been detected.

Amplia CEO and MD Dr Chris Burns commented: "We are excited to announce another confirmed partial response in the ongoing ACCENT trial. This latest PR brings the response rate for the ACCENT trial to 31%, considerably better than the 23% reported for the benchmark study of chemotherapy alone. Importantly, our study is still ongoing with 20 patients currently on study."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

About Narmafotinib

Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over- expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies.